Updated Jul 16, 2026
Guyer William has filed 4 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $21.09M.

William Guyer is the Chief Development Officer at Corcept Therapeutics Inc, a pharmaceutical company focused on developing treatments for disorders related to cortisol. He has been involved in multiple SEC filings related to the company's operations.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-08 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 952 | $93.54 | $89K |
| 2026-07-08 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 19.0K | $93.11 | $1.77M |
| 2026-07-08 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise | 20.0K | $21.65 | $433K |
| 2026-06-04 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 20.0K | $70.60 | $1.41M |
| 2026-06-04 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise | 20.0K | $21.65 | $433K |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 877 | $0.00 | |
| 2026-06-03 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 877 | $70.44 | $62K |
| 2026-05-07 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale | 20.0K | $51.83 | $1.04M |
| 2026-05-07 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise | 20.0K | $21.65 | $433K |
| 2026-04-08 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale [10b5-1] | 20.0K | $40.97 | $819K |
| 2026-04-08 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise [10b5-1] | 20.0K | $21.65 | $433K |
| 2026-03-24 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale [10b5-1] | 11.8K | $36.01 | $424K |
| 2026-03-24 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise [10b5-1] | 11.8K | $21.65 | $255K |
| 2026-03-06 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale [10b5-1] | 8.2K | $35.99 | $296K |
| 2026-03-06 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise [10b5-1] | 8.2K | $21.65 | $178K |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 498 | $0.00 | |
| 2026-03-05 | CORT | CORCEPT THERAPEUTICS INC | A — Grant or award | 498 | $35.97 | $18K |
| 2026-02-05 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale [10b5-1] | 20.0K | $40.87 | $817K |
| 2026-02-05 | CORT | CORCEPT THERAPEUTICS INC | M — Option exercise [10b5-1] | 20.0K | $21.65 | $433K |
| 2026-01-09 | CORT | CORCEPT THERAPEUTICS INC | S — Open-market sale [10b5-1] | 20.0K | $35.18 | $704K |
William Guyer is the Chief Development Officer at Corcept Therapeutics Inc, a pharmaceutical company focused on developing treatments for disorders related to cortisol. He has been involved in multiple SEC filings related to the company's operations.…
4 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 30 open-market sales ($21.09M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Guyer William profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.